{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:08:48Z","timestamp":1771423728626,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Scand J Trauma Resusc Emerg Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Septic shock remains one of the most lethal emergency and critical care conditions, with underlying pathophysiology closely linked to uncontrolled vasodilation mediated by nitric oxide activation of the soluble guanylate cyclase pathway (NO\u2013sGC\u2013cGMP pathway). Methylene blue (MB), through its inhibition of this pathway, has demonstrated hemodynamic benefits and may serve as a targeted adjunctive therapy particularly in patients with septic shock requiring high-dose vasopressors, a severely vasoplegic subpopulation characterized by markedly elevated mortality. However, large-scale randomized controlled trials (RCTs) evaluating MB treatment for mortality benefit in high-dose vasopressor-dependent septic shock patients are currently lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is an investigator-initiated, multicenter, open-label, blinded endpoint\u00a0RCT that will recruit adult septic shock patients requiring norepinephrine equivalent doses\u2009&gt;\u20090.3\u00a0\u03bcg\/kg\/min within 24\u00a0h of vasopressor initiation across multiple centers in China. A total of 566 patients will be randomized 1:1 to receive MB treatment (2\u00a0mg\/kg loading dose followed by 0.25\u00a0mg\/kg\/h maintenance infusion for up to 48\u00a0h or 4\u00a0h after vasopressor discontinuation) or equal volume 5% dextrose control. Randomization will be stratified by baseline SOFA-1 score and study center. The primary endpoint is 28-day all-cause mortality. Secondary outcomes include ICU-free days, vasopressor-free days, ventilator-free days, in-hospital mortality, and SOFA score improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This multicenter RCT will generate evidence on whether early MB administration reduces mortality in patients with high-dose vasopressor\u2013dependent septic shock, potentially informing clinical practice regarding MB's role as an adjunctive therapy in severe septic shock management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ChiCTR2500112352.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13049-026-01563-y","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:04:44Z","timestamp":1769256284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Methylene Blue for Mortality Reduction in High-Dose VasoPREssor-Dependent Septic Shock (EMPRESS): protocol for a multicenter randomized controlled trial"],"prefix":"10.1186","volume":"34","author":[{"given":"Jing-chao","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-hao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Ibarra-Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-ang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Teboul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"12","key":"1563_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00134-010-2045-8","volume":"36","author":"B Levy","year":"2010","unstructured":"Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med. 2010;36(12):2019\u201329.","journal-title":"Intensive Care Med"},{"issue":"4","key":"1563_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/CCM.0000000000005317","volume":"50","author":"GL Sacha","year":"2022","unstructured":"Sacha GL, Lam SW, Wang L, Duggal A, Reddy AJ, Bauer SR. Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock. Crit Care Med. 2022;50(4):614\u201323.","journal-title":"Crit Care Med"},{"issue":"11","key":"1563_CR3","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063\u2013143.","journal-title":"Crit Care Med"},{"issue":"8","key":"1563_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/17512433.2022.2110067","volume":"15","author":"TE Albertson","year":"2022","unstructured":"Albertson TE, Chenoweth JA, Lewis JC, Pugashetti JV, Sandrock CE, Morrissey BM. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock. Expert Rev Clin Pharmacol. 2022;15(8):959\u201376.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"1563_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s13181-013-0298-7","volume":"9","author":"DH Jang","year":"2013","unstructured":"Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote. J Med Toxicol. 2013;9(3):242\u20139.","journal-title":"J Med Toxicol"},{"issue":"5","key":"1563_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/BF01706481","volume":"18","author":"F Schneider","year":"1992","unstructured":"Schneider F, Lutun P, Hasselmann M, Stoclet JC, Tempe JD. Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations. Intensive Care Med. 1992;18(5):309\u201311.","journal-title":"Intensive Care Med"},{"issue":"9","key":"1563_CR7","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1007\/s12325-020-01422-x","volume":"37","author":"F Puntillo","year":"2020","unstructured":"Puntillo F, Giglio M, Pasqualucci A, Brienza N, Paladini A, Varrassi G. Vasopressor-sparing action of methylene blue in severe sepsis and shock: a narrative review. Adv Ther. 2020;37(9):3692\u2013706.","journal-title":"Adv Ther"},{"issue":"10","key":"1563_CR8","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1097\/00003246-200110000-00002","volume":"29","author":"MY Kirov","year":"2001","unstructured":"Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjornsson B, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001;29(10):1860\u20137.","journal-title":"Crit Care Med"},{"issue":"4","key":"1563_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.niox.2010.01.006","volume":"22","author":"NP Juffermans","year":"2010","unstructured":"Juffermans NP, Vervloet MG, Daemen-Gubbels CR, Binnekade JM, de Jong M, Groeneveld AB. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide. 2010;22(4):275\u201380.","journal-title":"Nitric Oxide"},{"key":"1563_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1014276","volume":"9","author":"S Sari-Yavuz","year":"2022","unstructured":"Sari-Yavuz S, Heck-Swain KL, Keller M, Magunia H, Feng YS, Haeberle HA, et al. Methylene blue dosing strategies in critically ill adults with shock-a retrospective cohort study. Front Med Lausanne. 2022;9:1014276.","journal-title":"Front Med Lausanne"},{"issue":"1","key":"1563_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13054-023-04397-7","volume":"27","author":"M Ibarra-Estrada","year":"2023","unstructured":"Ibarra-Estrada M, Kattan E, Aguilera-Gonzalez P, Sandoval-Plascencia L, Rico-Jauregui U, Gomez-Partida CA, et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care. 2023;27(1):110.","journal-title":"Crit Care"},{"issue":"1","key":"1563_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89934-w","volume":"15","author":"S Xue","year":"2025","unstructured":"Xue S, Li L, Liu Z, Lyu F, Wu F, Shi P, et al. Predicting responsiveness to fixed-dose methylene blue in adult patients with septic shock using interpretable machine learning: a retrospective study. Sci Rep. 2025;15(1):7254.","journal-title":"Sci Rep"},{"issue":"1","key":"1563_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04322-y","volume":"27","author":"Y Kotani","year":"2023","unstructured":"Kotani Y, Di Gioia A, Landoni G, Belletti A, Khanna AK. An updated \u201cnorepinephrine equivalent\u201d score in intensive care as a marker of shock severity. Crit Care. 2023;27(1):29.","journal-title":"Crit Care"},{"issue":"1","key":"1563_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-025-05250-9","volume":"29","author":"Y Kotani","year":"2025","unstructured":"Kotani Y, Di Gioia A, Landoni G, Belletti A, Khanna AK. Correction: An updated \u201cnorepinephrine equivalent\u201d score in intensive care as a marker of shock severity. Crit Care. 2025;29(1):104.","journal-title":"Crit Care"},{"issue":"9","key":"1563_CR15","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1007\/s00134-025-08053-2","volume":"51","author":"J D'Andria Ursoleo","year":"2025","unstructured":"D\u2019Andria Ursoleo J, Bottussi A, Khanna AK, Leone M, Wieruszewski PM, Monaco F. Norepinephrine pharmacolexicology: a chronological review of dose reporting and the implications of salt formulations. Intensive Care Med. 2025;51(9):1664\u201373.","journal-title":"Intensive Care Med"},{"issue":"8","key":"1563_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"key":"1563_CR17","doi-asserted-by":"crossref","unstructured":"Ranzani OT, Singer M, Salluh JIF, Shankar-Hari M, Pilcher D, Berger-Estilita J, Coopersmith CM, Juffermans NP, Laffey J, Reinikainen M et al. Development and validation of the sequential organ failure assessment (SOFA)-2 Score. JAMA. 2025;334(23):2090\u2013103.","DOI":"10.1001\/jama.2025.20516"},{"issue":"11","key":"1563_CR18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181\u2013247.","journal-title":"Intensive Care Med"},{"issue":"1","key":"1563_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40560-025-00776-0","volume":"13","author":"N Shime","year":"2025","unstructured":"Shime N, Nakada TA, Yatabe T, Yamakawa K, Aoki Y, Inoue S, et al. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024. J Intensive Care. 2025;13(1):15.","journal-title":"J Intensive Care"},{"issue":"11","key":"1563_CR20","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00134-025-08137-z","volume":"51","author":"X Monnet","year":"2025","unstructured":"Monnet X, Messina A, Greco M, Bakker J, Aissaoui N, Cecconi M, et al. ESICM guidelines on circulatory shock and hemodynamic monitoring 2025. Intensive Care Med. 2025;51(11):1971\u20132012.","journal-title":"Intensive Care Med"},{"issue":"1","key":"1563_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s13054-025-05669-0","volume":"29","author":"S Tongyoo","year":"2025","unstructured":"Tongyoo S, Chayakul C, Aritajati T, Tanyalakmara T. Adjunctive terlipressin versus placebo in the treatment of refractory septic shock: a randomized, placebo-controlled trial. Crit Care. 2025;29(1):443.","journal-title":"Crit Care"},{"issue":"1","key":"1563_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07543-8","volume":"22","author":"YC Liu","year":"2022","unstructured":"Liu YC, Yao Y, Yu MM, Gao YL, Qi AL, Jiang TY, et al. Frequency and mortality of sepsis and septic shock in China: a systematic review and meta-analysis. BMC Infect Dis. 2022;22(1):564.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1563_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.clnu.2019.02.020","volume":"39","author":"H Ohbe","year":"2020","unstructured":"Ohbe H, Jo T, Matsui H, Fushimi K, Yasunaga H. Differences in effect of early enteral nutrition on mortality among ventilated adults with shock requiring low-, medium-, and high-dose noradrenaline: a propensity-matched analysis. Clin Nutr. 2020;39(2):460\u20137.","journal-title":"Clin Nutr"},{"key":"1563_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jcrc.2020.02.014","volume":"57","author":"R Domizi","year":"2020","unstructured":"Domizi R, Calcinaro S, Harris S, Beilstein C, Boerma C, Chiche JD, et al. Relationship between norepinephrine dose, tachycardia and outcome in septic shock: a multicentre evaluation. J Crit Care. 2020;57:185\u201390.","journal-title":"J Crit Care"},{"issue":"7","key":"1563_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jama.2019.0071","volume":"321","author":"G Hernandez","year":"2019","unstructured":"Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019;321(7):654\u201364.","journal-title":"JAMA"},{"issue":"1","key":"1563_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-080065","volume":"14","author":"X Huang","year":"2024","unstructured":"Huang X, Yan W, Chen Z, Qian Y. Effect of methylene blue on outcomes in patients with distributive shock: a meta-analysis of randomised controlled trials. BMJ Open. 2024;14(1):e080065.","journal-title":"BMJ Open"},{"key":"1563_CR27","doi-asserted-by":"crossref","unstructured":"Alkazemi A, Almoosawy SA, Murad A, Alfares A. Methylene blue for septic shock: a systematic review and meta-analysis of randomized and prospective observational studies. J Intensive Care Med. 2026;41(2):108\u201317.","DOI":"10.1177\/08850666241300312"},{"issue":"1","key":"1563_CR28","volume":"75","author":"KT Ng","year":"2025","unstructured":"Ng KT, Kwok PE, Lim WE, Teoh WY, Hasan MS, Zainal Abidin MF. The use of methylene blue in adult patients with septic shock: a systematic review and meta-analysis. Braz J Anesthesiol. 2025;75(1):844580.","journal-title":"Braz J Anesthesiol"},{"issue":"3","key":"1563_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1590\/S0102-76382009000400005","volume":"24","author":"PR Evora","year":"2009","unstructured":"Evora PR, Ribeiro PJ, Vicente WV, Reis CL, Rodrigues AJ, Menardi AC, et al. Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties. Rev Bras Cir Cardiovasc. 2009;24(3):279\u201388.","journal-title":"Rev Bras Cir Cardiovasc"},{"issue":"3","key":"1563_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00024382-199903000-00002","volume":"11","author":"AB Groeneveld","year":"1999","unstructured":"Groeneveld AB, Hartemink KJ, de Groot MC, Visser J, Thijs LG. Circulating endothelin and nitrate-nitrite relate to hemodynamic and metabolic variables in human septic shock. Shock. 1999;11(3):160\u20136.","journal-title":"Shock"},{"issue":"6","key":"1563_CR31","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1161\/01.RES.74.6.1121","volume":"74","author":"JF Keaney Jr.","year":"1994","unstructured":"Keaney JF Jr., Puyana JC, Francis S, Loscalzo JF, Stamler JS, Loscalzo J. Methylene blue reverses endotoxin-induced hypotension. Circ Res. 1994;74(6):1121\u20135.","journal-title":"Circ Res"},{"issue":"4","key":"1563_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0883-9441(98)90001-6","volume":"13","author":"M Andresen","year":"1998","unstructured":"Andresen M, Dougnac A, Diaz O, Hernandez G, Castillo L, Bugedo G, et al. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care. 1998;13(4):164\u20138.","journal-title":"J Crit Care"},{"issue":"12","key":"1563_CR33","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/BF01700666","volume":"21","author":"B Gachot","year":"1995","unstructured":"Gachot B, Bedos JP, Veber B, Wolff M, Regnier B. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med. 1995;21(12):1027\u201331.","journal-title":"Intensive Care Med"},{"issue":"5","key":"1563_CR34","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1213\/ANE.0000000000004325","volume":"129","author":"LQ Rong","year":"2019","unstructured":"Rong LQ, Mauer E, Mustapich TL, White RS, Di Franco A, Girardi LN, et al. Characterization of the rapid drop in pulse oximetry reading after intraoperative administration of methylene blue in open thoracoabdominal aortic repairs. Anesth Analg. 2019;129(5):e142\u20135.","journal-title":"Anesth Analg"}],"container-title":["Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13049-026-01563-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13049-026-01563-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13049-026-01563-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:26:54Z","timestamp":1771421214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13049-026-01563-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1563"],"URL":"https:\/\/doi.org\/10.1186\/s13049-026-01563-y","relation":{},"ISSN":["1757-7241"],"issn-type":[{"value":"1757-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial adheres to the Declaration of Helsinki principles and GCP guidelines. The study has been approved by the Ethics Committee of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (Ethics approval number: 2025\u2013583), the sponsor and lead institution, and will require approval from ethics committees of all participating centers. The trial is registered in the Chinese Clinical Trial Registry (ChiCTR2500112352). Informed consent will be obtained from either the patients themselves or their legally authorized representatives, depending on the patient\u2019s decision-making capacity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}